Yahoo · Nov 1, 2026
What to expect from Jazz Pharmaceuticals’s (JAZZ) Q3 earnings
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be reporting results this Monday after market hours. Here’s what to expect.
NASDAQ · JAZZ
Jazz Pharmaceuticals plc
Healthcare · Biotechnology
$214.44
Down-$1.54 (-0.71%)
Updated Nov 3, 2026, 9:11 AM
SID Score
5.5/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 10.02B
- P/E ratio
- -27.16
- Dividend yield
- 0.00%
- 52-week range
- $156.95 – $266.38
- Volume
- 1.07M
- Avg. volume
- 1.03M
Price performance · JAZZ
JAZZ price history
1M range · 0 trading sessions · Daily adjusted prices
JAZZ does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest JAZZ news
The latest Smart Investors Daily articles mentioning JAZZ.
Stock researchCompany · Overview
Company
Market Activity
Research & News
JAZZ research
Overview
Company profile and research snapshot.
Company profile
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $190.43
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 28, 2026 | JP Morgan | Overweight | — |
| Oct 21, 2026 | Morgan Stanley | Overweight | — |
| Oct 8, 2026 | RBC Capital | Outperform | — |
| Oct 7, 2026 | Truist Securities | Buy | — |
| Sep 30, 2026 | Citigroup | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 30, 2026
With Setara, the team behind Actio opens its second act
The fledgling startup has $90 million to develop a pipeline of drugs, led by a Charcot-Marie-Tooth disease medicine, that Actio was working on when Jazz Pharmaeuticals bought its lead epilepsy program.
Yahoo · Oct 30, 2026
Setara Biosciences Announces $90 Million Series A Financing to Advance Precision Medicines for Rare Genetic Diseases and Related Expansion Indications
SAN DIEGO, October 30, 2026--Setara Biosciences, Inc. (Setara), a clinical-stage biotechnology company leveraging genetics to develop precision medicines for severe rare diseases, today announced the completion of a $90 million Series A financing. Setara was formed following the closing of Jazz Pharmaceuticals’ acquisition of Actio Biosciences (Actio) for its lead program ABS-1230, an investigational therapy for KCNT1-related epilepsy. Setara intends to advance Actio’s remaining pipeline, led by
Benzinga · Oct 28, 2026
JP Morgan Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $300
JP Morgan analyst Jessica Fye maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $276 to $300.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
